Development · 20 Sep 2026
3 publishers have reported this development. Each act of reporting is below, cited.
Gujarat Themis Biosyn Limited completed the acquisition of MicroBiopharm Japan Co., Ltd. for ¥21.5 billion (Rs 1,300 crore).
Gujarat Themis Biosyn announced the completion of the acquisition of 100% equity shareholding in MicroBiopharm Japan Co. (MBJ), Japan, through Themis Biosyn Japan, a wholly owned subsidiary incorporated in Japan.
Gujarat Themis Biosyn has completed the acquisition of 100 per cent equity shareholding in MicroBiopharm Japan Co., Ltd. for a total consideration of JPY 21.5 billion.
This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.
New here? The reader's guide explains every page, plate by plate.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.